in medication, unless a contraindication exists.
3. All patients undergoing CEA should be maintained
on either single or dual antiplatelet medication
throughout the perioperative period, unless a contraindication exists.
4. Patient with a coronary drug-eluting stent should be
maintained on dual antiplatelet medications whenever feasible.
5. Early recognition of perioperative MI should occur to
allow appropriate individualized therapy including
medical or pharmacologic interventions, or urgent
